Mitral valve annuloplasty double by the year 2030. Every year, 300,000 people worldwide undergo open heart surgery for mitral valve repair, 44,000 people in the US alone. Since it was initially established 40 years ago by Professor Alain Carpentier, mitral valve annuloplasty has been continuously improved and is considered the gold standard for the treatment of most etiologies of mitral valve dysfunction today. The goal of mitral valve annuloplasty is to regain mitral valve competence by restoring the physiological form and function of the normal mitral valve apparatus. Under normal conditions the mitral valve undergoes significant dynamic changes in shape and size throughout
Mitral valve annuloplasty Drug Administration (FDA) as medical devices. Mitral valve annuloplasty Mitral valve annuloplasty is a surgical technique for the repair of leaking mitral valves. Due to various factors, the two leaflets normally involved in sealing the mitral valve to retrograde flow may not coapt properly. Surgical repair typically involves the implantation of a device surrounding the mitral valve, called an annuloplasty device, which pulls the leaflets together to facilitate coaptation and aids to re-establish mitral valve function. Mitral regurgitation is the most common form of mitral valve dysfunction. Today more than 2.5 million Americans are estimated to be affected by mitral